HUMA Humacyte, Inc.
Legal ·
The North Carolina class action names Humacyte and certain officers. Derivative suits name current or former directors and officers, and Ayabudge LLC in two cases. Product safety claims survived dismissal.
Nasdaq told Humacyte on May 4, 2026 that its common stock closed below $1.00 for 30 consecutive business days. The company has until November 2, 2026 to regain compliance, and the notice has no immediate effect on its listing.
Humacyte is selling 28,436,018 shares, with warrants for the same number of shares, at $2.11 per share and warrant. The release does not say how the proceeds will be used.
Humacyte is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. It began the United States commercial launch of its first FDA-approved product, Symvess (acellular tissue engineered vessel-tyod, or ATEV), in the first quarter of 2025. The company believes its regenerative medicine technology has the potential to overcome limitations in existing standards of care. Its strategic partnership with Fresenius Medical Care Holdings covers the sale, marketing and distribution of its 6 millimeter ATEV for certain specified indications and markets, if approved by regulatory authorities. Humacyte is running the Phase 3 V007 and V012 clinical trials and has ongoing discussions with the FDA about the design of its clinical trials. The company also relies on third-party manufacturers, licensors and suppliers, and it says it must manufacture its products in sufficient quantities to satisfy clinical trial and commercial needs.
| Product or program | What it is | Stage |
|---|---|---|
| Symvess (acellular tissue engineered vessel-tyod, ATEV) | Bioengineered tissue vessel for implantation, first FDA-approved product | approved in the US |
| 6 millimeter ATEV | Vessel to be sold with Fresenius Medical Care for specified indications and markets |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.0 million | $0 |
| Research and development | $69.3 million | $88.6 million |
| Net income (loss) | -$40.8 million | -$148.7 million |
| Cash from operations | -$105.0 million | -$98.1 million |
| Cash and equivalents | $50.5 million | $44.9 million |
Our latest story on this, dated Aug 12, 2026: "Humacyte securities suit over Symvess safety enters discovery; four derivative suits pending". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 7, 2025: "Humacyte prices $60.0 million registered direct offering of stock and warrants". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 8, 2026: "Humacyte gets Nasdaq minimum bid price deficiency notice, has until November 2, 2026". The story links the filing or release it is based on. Read the story.
Humacyte, Inc. trades under the ticker HUMA on NASDAQ.
Humacyte, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Humacyte, Inc. is 1818382. Its filings are on SEC EDGAR.
277,798,105 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Humacyte, Inc. under United States.
Our directory classifies Humacyte, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Humacyte, Inc. is US44486Q1031.
aibio.space lists Humacyte, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Humacyte is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. It began the United States commercial launch of its first FDA-approved product, Symvess (acellular tissue engineered vessel-tyod, or ATEV), in the first quarter of 2025.
Symvess (acellular tissue engineered vessel-tyod, ATEV): Bioengineered tissue vessel for implantation, first FDA-approved product Stage: approved in the US.
6 millimeter ATEV: Vessel to be sold with Fresenius Medical Care for specified indications and markets
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio